关键信息
-
基因名
PCI
- 应用
-
别名
PCI；PCI domain-containing Protein 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P05154
-
表达区间
1-406aa
-
氨基酸序列
MQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAAPSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQTKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSREDQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLELYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGTRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
The study of PCI (Plasminogen Activator Inhibitor-1) recombinant proteins has gained significant attention in recent years due to their crucial roles in various physiological and pathological processes, particularly in regulating fibrinolysis, inflammation, and cellular signaling. PCI serves as an important inhibitor of tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), key enzymes in the conversion of plasminogen to plasmin, which is essential for the dissolution of blood clots. Dysregulation of PCI levels has been implicated in a range of diseases, including cardiovascular disorders, cancer, and metabolic syndromes. As a result, the development of recombinant PCI proteins has become a focal point for potential therapeutic interventions, aiming to modulate its activity for clinical benefits. Advances in recombinant DNA technology have enabled the production of these proteins with improved efficacy and stability, facilitating detailed studies on their structure-function relationships. Through this research, scientists are exploring the potential of PCI recombinant proteins as biomarkers for disease progression and as targets for novel treatment strategies. Furthermore, understanding the molecular mechanisms underlying PCI's interactions with serine proteases provides insights into the broader implications of fibrinolytic regulation and its impact on human health. The emerging findings in this field not only contribute to our understanding of coagulation and its disorders but also open avenues for innovative therapies aimed at restoring balance in the fibrinolytic system.
